Close Menu

drug development

Genetic and phenotypic data for Million Veteran Program participants led to loss-of-function changes in a gene inhibited by cilostazol.

Organizers of a data analysis challenge remain hopeful that a recent update to the Connectivity Map resource will lead to breakthroughs in DILI detection by next year.

Backed by Andreessen Horowitz and Polaris Partners, Camp4 hopes its high-resolution gene maps can shorten and remove risk from the drug development process.

Saturation mutagenesis of the human malaria parasite Plasmodium falciparum identified almost 2,700 essential genes during the blood stage of infection.

By sequencing and characterizing the genome of Artemisia annua, researchers uncovered gene expansions and regulatory features linked to artemisinin production.

With multiple independent biomarkers, and potential combinations that may require even more subtyping, diagnostics to guide immunotherapy appears to be getting more complicated.

Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.